ESC
A proposed multi-ingredient blend designed for cardiovascular health support, combining botanical compounds, selected nutrients and a delivery concept for the lipophilic fraction.
Mean fasting LDL-C (mg/dL) · percentage changes are from baseline · n = 140 (70 per arm), adults with dyslipidemia.
Randomized, double-blind, placebo-controlled study; n = 140 (70 per arm), adults with dyslipidemia. Percentage changes are from baseline. Chart values in mg/dL, rounded to one decimal.
A proposed multi-ingredient blend built around botanical compounds and selected nutrients for lipid metabolism, vascular, antioxidant and inflammatory-balance support.
Omega-3 · Bergamot · Berberine.
L-citrulline · Magnesium · K2.
ALA · Astaxanthin · EGCG.
Curcumin · Resveratrol · BCP.
These are potential positioning areas, not established Q-Lumeniva health benefits. Product-specific substantiation is required.
Several of the formulation's botanical actives sit in the lipophilic fraction, which can face poor dissolution and limited systemic exposure. Q-LUMENIVA pairs two QuanticSphere™ technologies — one for its phytosome actives, one for its minerals — giving brands a cardiovascular-health proposition built around engineered delivery.
Phytosome-complexed nanosphere vesicles are designed to improve dissolution, enhance uptake, and increase AUC.
Minerals (Mg, Mn) are nano-chelated within a biopolymer matrix. They are protected from gastric conditions and released at intestinal pH for optimized mineral delivery.
Several of Q-Lumeniva's botanical actives sit in the lipophilic fraction, which can face poor dissolution and limited systemic exposure. Q-LUMENIVA is designed to address that delivery challenge with QuanticSphere™ PQNS and MIBS technology.
In a randomized, double-blind, placebo-controlled study (n=140, 70 per arm) in adults with dyslipidemia, the studied formulation showed mean reductions from baseline to week 12 of 31.4% in LDL-C and 36.8% in triglycerides, and a mean increase of 12.7% in HDL-C, compared with 3.1%, 2.8% and 0.9% respectively for placebo. This is clinical evidence for the studied formulation and is not, on its own, a substantiated health claim for Q-Lumeniva as marketed — product-specific substantiation is required.
QuanticSphere™ PQNS (Phytosome Quantum Nano Sphere) uses phytosome-complexed nanosphere vesicles designed to improve dissolution, enhance uptake, and increase AUC. QuanticSphere™ MIBS (Mineral Ion Biopolymer Sphere) nano-chelates minerals (Mg, Mn) within a biopolymer matrix, protecting them from gastric conditions and releasing them at intestinal pH for optimized mineral delivery.
Cardiovascular health support, healthy circulation support, and antioxidant support. These are potential positioning areas, not established Q-Lumeniva health benefits — product-specific substantiation is required.
Facility: NSF/ANSI 455-2 certified GMP, FSSC 22000, ISO 9001/14001/45001. Regulatory: 21 CFR Part 111, Halal Certified. Dissolution: approximately 95–100% release, batch-consistent. IP: QuanticSphere™ PQNS, patent pending 202521095813.
Share your formulation requirements and our team can walk you through the full Q-Lumeniva clinical dossier, supply format and technical specifications.
Talk to a Specialist